- Home
- SRTS vs CRBU Comparison
SRTS vs CRBU Comparison
Compare SRTS & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- CRBU
- Stock Information
- Founded
- SRTS 2010
- CRBU 2011
- Country
- SRTS United States
- CRBU United States
- Employees
- SRTS N/A
- CRBU N/A
- Industry
- SRTS Medical/Dental Instruments
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- SRTS Health Care
- CRBU Health Care
- Exchange
- SRTS Nasdaq
- CRBU Nasdaq
- Market Cap
- SRTS 88.7M
- CRBU 93.0M
- IPO Year
- SRTS 2016
- CRBU 2021
- Fundamental
- Price
- SRTS $4.77
- CRBU $0.95
- Analyst Decision
- SRTS Strong Buy
- CRBU Strong Buy
- Analyst Count
- SRTS 3
- CRBU 5
- Target Price
- SRTS $13.00
- CRBU $11.80
- AVG Volume (30 Days)
- SRTS 122.0K
- CRBU 995.9K
- Earning Date
- SRTS 05-08-2025
- CRBU 03-10-2025
- Dividend Yield
- SRTS N/A
- CRBU N/A
- EPS Growth
- SRTS 1266.06
- CRBU N/A
- EPS
- SRTS 0.41
- CRBU N/A
- Revenue
- SRTS $41,807,000.00
- CRBU $9,994,000.00
- Revenue This Year
- SRTS $9.09
- CRBU $3.50
- Revenue Next Year
- SRTS $22.30
- CRBU $177.84
- P/E Ratio
- SRTS $11.71
- CRBU N/A
- Revenue Growth
- SRTS 71.31
- CRBU N/A
- 52 Week Low
- SRTS $3.09
- CRBU $0.88
- 52 Week High
- SRTS $9.33
- CRBU $5.15
- Technical
- Relative Strength Index (RSI)
- SRTS 44.90
- CRBU 40.45
- Support Level
- SRTS $4.46
- CRBU $0.88
- Resistance Level
- SRTS $4.93
- CRBU $1.01
- Average True Range (ATR)
- SRTS 0.20
- CRBU 0.08
- MACD
- SRTS 0.09
- CRBU 0.01
- Stochastic Oscillator
- SRTS 69.35
- CRBU 42.00
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.